BIOA BioAge Labs, Inc. Insider Trading

CEO Fortney Kristen sells 233,107 shares of BIOA at $18.12 for $4.2M; retains 976,949 shares amid unprofitable operations.

Kristen, as Chief Executive Officer, sold 233,107 shares at $18.12, reducing her holdings by 19.3% from 1.21M to 976.9K shares. The company reported negative net income of $-20.2M against quarterly revenue of $2.1M, indicating ongoing unprofitability. The transaction occurred at $18.12, trading 6.2% below the 52-week high of $22.92, despite a sharp 71.9% gain over the prior 30 days and 315.2% surge over 90 days. The combination of substantial insider share reduction during a period of significant recent price appreciation, concurrent with documented operating losses, merits close attention to whether this disposal reflects capital-raising requirements or reflects management's assessment of near-term value relative to longer-term fundamentals.

BioAge Labs CFO sells 27,000 shares ($531.8K) across 4 transactions; retains 22,408 shares post-sale

CFO Dov Goldstein sold 27.0K shares over four separate transactions on 2026-01-13 at prices ranging from $18.43 to $21.08, generating $531,827.69 in aggregate proceeds and reducing his holdings by 54.6%. The sales occurred during a period of significant stock appreciation—the stock has risen 71.9% over 30 days and 315.2% over 90 days, and currently trades at $21.51, near its 52-week high of $22.92. BioAge Labs remains unprofitable on a full-year basis with net income of $-20,171,000.00 against quarterly revenue of only $2,054,000.00, indicating the company is pre-revenue or in early commercialization with substantial operating losses. The combination of material share reduction, elevated stock price relative to historical range, and persistent large-scale losses creates a notable signal about capital deployment priorities at a cash-constrained biotech firm.

BioAge Labs CMO Paul Rubin liquidates entire 68.9K share stake at $10.19, exiting $701.9K position

Paul Rubin, Chief Medical Officer, executed a complete exit of his equity stake, selling 68,897 shares for $701,908.86 and reducing his post-transaction holdings to 0 shares. The company is operating at significant losses ($-20,171,000.00 net income in the latest period) against quarterly revenue of only $2,054,000.00, indicating BioAge Labs is burning cash substantially faster than it generates sales. The sale occurred at $10.19 on 2025-12-04, below the current market price of $11.61 and well below the 52-week high of $20.09, yet the stock has surged 54.8% over the 30-day prior period despite deteriorating fundamentals. A complete equity liquidation by the CMO—a core scientific and operational leadership role in a clinical/biotech context—represents a decisive shift in insider exposure and warrants investor scrutiny of the company's clinical pipeline status and cash runway expectations.

Principal Accounting Officer Barton Shane bought 2,632 shares of BIOA at $18.00 (first position); stock now $4.33, -83.2% from 52-week high.

Barton Shane, serving as Principal Accounting Officer, purchased 2,632 shares at $18.00 on 2024-09-27, establishing his first recorded position in BioAge Labs. The timing is notable: the purchase price of $18.00 was significantly closer to the 52-week high of $25.83 than to today's current price of $4.33, representing a -83.2% decline from the 52-week peak. The company is currently unprofitable with net income of -$23.4M against a market cap of $155.2M, indicating substantial operational losses. The sharp gap between the insider's entry price and the current valuation warrants attention to whether fundamental deterioration occurred post-purchase or whether market conditions shifted materially after the transaction date.

Director Pande Vijay Satyanand bought 219,195 shares for $4,329,019.37 across 3 transactions (Oct 1-3) at $19.75 blended average; concurrent cluster buy by 4 other insiders.

Pande Vijay Satyanand, a director at BioAge Labs, executed 3 separate purchases totaling 219,195 shares for $4,329,019.37 between October 1 and October 3, 2024, increasing his holdings by 24.4% from 900,000 shares to 1,119,195 shares. The blended average purchase price of $19.75 sits 5.3% below the current price of $20.86, though comparisons are constrained by the company's recent listing status (6 trading days). Notably, 4 other insiders also bought within the same 14-day window, forming a cluster purchase pattern that suggests coordinated conviction among the insider group. The scale of Pande's personal acquisition—a significant near-$4.3M commitment—combined with the simultaneous buying activity by multiple officers and directors, indicates material confidence in the stock near its market introduction.

Cormorant Asset Management bought 450,000 BIOA shares at $18.00 (9.1% under current price) in 4-day-old IPO; +38.2% to holdings amid cluster buy pattern.

Cormorant Asset Management purchased 450,000 shares at $18.00 on 2024-09-27, increasing its post-transaction holdings to 1,629,529 shares, a +38.2% increase from 1,179,529 shares. The purchase price sits $2.25 below the current price of $20.25 as of 2024-10-01, four trading days after the transaction. This activity is part of a cluster of 4 other insider buys within the past 14 days, indicating coordinated accumulation during the stock's nascent public trading period. The filing contains a derivative-conversion component (Form 4 Table II), so the reported Table I position does not represent Cormorant's complete holdings and should be interpreted as a partial measure of equity exposure.

Director Pande Vijay Satyanand bought 900,000 shares of BIOA at $18.00 ($16.2M) post-IPO; 4 other insiders bought within 14 days.

Director Pande Vijay Satyanand purchased 900,000 shares at $18.00 for a total value of $16,200,000.00, establishing an initial position in BioAge Labs just 2 trading days after the company's recent IPO listing. This transaction carries the FLAG that it involves a conversion of derivative securities, so the Form 4 Table I shares_after figure does not represent the director's total position—the full holding picture resides in Table II derivatives, which are not yet populated in the database. Notably, 4 other insiders also executed purchases within the past 14 days, forming a coordinated insider buying cluster immediately following the listing. This pattern of multi-insider acquisition activity in the IPO window is material and warrants investor attention as a signal of confidence from multiple members of the company's leadership team during the critical early-trading period.

Director Patrick Enright purchased 400,000 shares of BIOA at $18.00 ($7.2M) in post-IPO window; 4 insiders buying within 14 days

Director Patrick Enright purchased 400,000 shares at $18.00 on 2024-09-27, increasing his holdings from 1,310,589 shares to 1,710,589 shares—a +30.5% increase in his equity stake. The transaction occurs just 2 trading days after BioAge Labs' recent listing and at a price $3.00 below the current $21.00 market price. Notably, a cluster pattern shows 4 other insiders also bought within the past 14 days, suggesting coordinated accumulation during the early public trading window. This filing contains a derivative-conversion transaction; the full extent of Enright's position includes securities in Table II that are not yet populated in the database, so reported Table I holdings represent only a portion of his beneficial interest.

Director James Healy bought 666,665 shares at $18.00 ($12.0M); cluster pattern with 4 other insiders buying within 14 days

Director James Healy executed 5 separate purchases totaling 666,665 shares for $11,999,970.00 at $18.00 per share on 2024-09-27. The transaction occurred in a context of recent listing (just 2 trading days), where the current market price is $21.00. This substantial acquisition is noteworthy because 4 other insiders also bought within the past 14 days, forming a cluster buy pattern. The filing contains a derivative conversion (Form 4 Table II), meaning the 26,497 shares shown in Table I post-transaction represents only a portion of the director's total position; the derivative holdings are not yet populated in the database. This multi-insider buying activity in the days following a stock listing suggests coordinated confidence or planned accumulation tied to the IPO process.